Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2016 - 2020)

Agios Pharmaceuticals (AGIO) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $491000.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Non-Current Deffered Revenue fell 99.05% year-over-year to $491000.0, compared with a TTM value of $491000.0 through Jun 2020, down 99.05%, and an annual FY2019 reading of $50.6 million, down 15.43% over the prior year.
  • Non-Current Deffered Revenue was $491000.0 for Q2 2020 at Agios Pharmaceuticals, down from $50.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $183.5 million in Q2 2016 and bottomed at $491000.0 in Q2 2020.
  • Average Non-Current Deffered Revenue over 5 years is $50.4 million, with a median of $34.2 million recorded in 2016.
  • The sharpest move saw Non-Current Deffered Revenue soared 1074.21% in 2016, then plummeted 99.05% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $154.3 million in 2016, then tumbled by 88.23% to $18.2 million in 2017, then soared by 229.44% to $59.8 million in 2018, then decreased by 15.43% to $50.6 million in 2019, then plummeted by 99.03% to $491000.0 in 2020.
  • Business Quant data shows Non-Current Deffered Revenue for AGIO at $491000.0 in Q2 2020, $50.6 million in Q4 2019, and $49.8 million in Q3 2019.